Le Lézard
Classified in: Health, Business
Subjects: CXP, MAT

CannTrust to Start Trading on NYSE Today


For more media materials, please visit: https://www.multivu.com/players/English/8501851-canntrust-nyse-uplisting/

VAUGHAN, ON, Feb. 25, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX:TRST, NYSE:CTST) is pleased to announce that its common shares will begin trading on the New York Stock Exchange ("NYSE") today.

CannTrust Holdings Inc. (CNW Group/CannTrust Holdings Inc.)

CannTrust's shares will trade on the NYSE under the ticker symbol "CTST". The Company's common shares will continue to be listed on the Toronto Stock Exchange under the ticker symbol "TRST".

Shareholders that purchased common shares on the OTC Markets Pink Open Market may now trade their shares on the NYSE.

"We are a fast-growing company that is continuously looking to increase our international presence," said Peter Aceto, Chief Executive Officer. "The NYSE listing is another significant milestone in the evolution of CannTrust and we are excited to share more about our planned growth initiatives in the near future."

About CannTrust
CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada, and the 2018 Canadian Cannabis Awards "Top Licensed Producer of the Year". Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry and serves more than 63,000 medical patients with its dried, extract and capsule products. The Company operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility in Pelham, Ontario, has been permitted to construct another 390,000 sq. ft. facility in Pelham, and prepares and packages its product portfolio at its 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.

CannTrust is developing nanotechnology to develop new products in the medical, recreational, beauty, wellness and pet markets. The Company has established its international footprint through a strategic partnership with Cannatrek Ltd. in Australia and a joint venture with STENOCARE in Denmark. The Company has also partnered with Breakthru Beverage Group through Kindred Canada, for recreational distribution in Canada. CannTrust is committed to research and innovation through partnerships with McMaster University in Ontario and Gold Coast University in Australia, which were designed to contribute to the growing body of evidence-based research regarding the use and efficacy of cannabis.

For more information, please visit www.canntrust.ca.

Forward Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws and such statements are based upon CannTrust's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.

The forward-looking information and statements in this news release are based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information and statements includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information and statements necessarily involve known and unknown risks, including, without limitation: risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States and elsewhere; the cannabis industry in Canada generally; and, the ability of CannTrust to implement its business strategies.

Any forward-looking information and statements speak only as of the date on which they are made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking information and statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust's Annual Information Form dated March 29, 2018 (the "AIF") and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and filed as an exhibit to CannTrust's Form 40-F registration statement under the United States Securities Exchange Act of 1934, as amended, with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. The risk factors and other factors noted in the AIF could cause actual events or results to differ materially from those described in any forward-looking information or statements.

The TSX and NYSE do not accept responsibility for the adequacy or accuracy of this release.

Copyright © 2019 CannTrust Holdings Inc.

SOURCE CannTrust Holdings Inc.


These press releases may also interest you

at 08:55
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of...

at 08:53
According to the Corporate Whistleblower Center, "We have by far the most robust initiative in the nation related to extremely short-staffed long-term care facilities billing Medicare-Medicaid as if they were fully staffed. In August of 2023 we...

at 08:52
Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will...

at 08:50
Response Pharmaceuticals, Inc., a clinical stage company focused on weight management and metabolic health in high-risk populations, today announced positive topline results from its Phase 1b clinical trial evaluating the safety and efficacy of...

at 08:47
Dr. Mary C. McCluskey, psychotherapist, and author revitalizes Dr. Alfred Adler, the "Pioneer in the Prevention of Mental Health Disorders" and Dr. Pierre Janet "Father of Trauma Treatment Theory" using a time-traveling hot air balloon to create a...

at 08:45
The "Peptide Synthesis: Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of...



News published on and distributed by: